What healthcare buyers actually pay a premium for in 2026.
In 2026, UAE healthcare buyers pay premiums for payer mix, RCM quality, clinical governance, and licence portability. Sellers price the wrong things.
What a board member needs before the next meeting on this.
- Buyers price payer mix, not revenue. Who pays, at what tariff, and how reliably; a single low-margin payer is a concentration risk a buyer discounts for.
- RCM quality is recoverable margin in plain sight. A weak revenue cycle can raise a buyer's price and transfer that value to them, at a discount, not to you.
- Clinical governance is where liabilities live. Buyers now treat it as its own diligence stream, not a compliance footnote — the quiet settlement, the credentialing gap.
- Licence portability is the one sellers forget. A licence that doesn't transfer cleanly is a liability dressed as an asset, worse where an asset spans DHA and DoH.
Most healthcare sellers price the wrong things. They point at revenue growth, bed count, and a marquee physician or two. They build the pitch around the top line. Then a buyer runs diligence, and the price moves for reasons the seller never put on a slide.
The gap is widening. In 2026 the UAE healthcare buyer pool is more sophisticated than it was five years ago. Regional funds have done this before. Strategic acquirers have integrated assets and been burned by the ones that looked clean and were not. They no longer pay for the story. They pay for the things that survive contact with an integration plan. Four of them.
Payer mix, not revenue
A dirham of cash-pay revenue and a dirham of low-tariff insurance revenue are not worth the same, and experienced buyers price them differently. What matters is not how much the business bills but who pays it, at what tariff, and how reliably. A group heavy in a single low-margin payer carries a concentration risk a buyer will discount for. A balanced book with durable contracts and defensible tariffs earns the premium. Sellers report revenue as one number. Buyers decompose it, and the decomposition is where the price is set.
RCM quality, because it is recoverable margin sitting in plain sight
Revenue cycle management is the least glamorous line in the business and the one buyers scrutinise hardest, because it is where value hides. Coding accuracy, denial rates, days in accounts receivable, collection velocity. A buyer who sees a leaky revenue cycle does not only discount for the leak. They see upside they can capture after close, which changes what they are willing to pay and how they structure the earn-out. Here is the part sellers miss: a weak revenue cycle can raise a buyer's price, because the buyer is confident they can fix it. But the seller captured none of that value. It transferred at a discount to the party who fixes it.
Clinical governance, because it is where the undisclosed liabilities live
The accounts show the revenue. They do not show the incident that was settled quietly, the credentialing gap, the standard that was not met. Buyers now treat clinical governance as a diligence stream in its own right, not a compliance footnote. A group with real governance, documented and functioning, removes a category of risk from the buyer's model. A group without it hands the buyer a reason to discount hard or walk, and in a competitive process, walking is easy.
Licence portability, the one sellers rarely think about at all
A licence attached to a person, a premises, or a scope that does not transfer cleanly is a liability wearing the costume of an asset. When ownership changes, does the operating licence survive? Do the physician licences move? Does the scope of practice hold under the new owner? In the UAE this is not a formality, and it differs between DHA and DoH jurisdictions, which turns a single asset into two regulatory problems if it spans both. A buyer who finds a portability gap prices the re-licensing risk and the downtime into the offer. A seller who closed the gap before going to market removes that discount entirely.
The pattern across all four is the same. Sellers value the business as it earns today. Buyers value it as it transfers and integrates tomorrow. The premium sits in the second view, and it is almost entirely inside the seller's control before a process starts. The revenue cycle can be cleaned. The payer book can be rebalanced. Governance can be documented. Portability can be confirmed and, where broken, fixed. Every one of these is a lever the seller can pull months ahead of a sale, and every one of them moves the price.
The buyers already run their diligence this way. The sellers who prepare against the same checklist do not get surprised in the data room, and they do not leave the premium on the table.
Four questions before you go to market
- Have we decomposed revenue by payer, tariff and durability the way a buyer will?
- What do our denial rate and days-in-AR say a buyer can capture after close?
- Is our clinical governance documented and functioning, or a footnote?
- Does every operating and physician licence survive a change of ownership, across DHA and DoH?
If you are preparing a healthcare business for sale, the time to price what buyers pay for is before they start looking, not after. That preparation is exactly where our sell-side M&A practice begins.